Thirty-day major adverse events and long-term follow-up
| Unmatched Cohort | Matched Cohort | |||||
|---|---|---|---|---|---|---|
| Near-Occlusion (n = 84 Patients) | Control Group (n = 460 Patients) | P Value | Near-Occlusion (n = 84 Patients) | Control Group (n = 168 Patients) | P Value | |
| TIA during hospitalization (No.) (%) | 6 (7.1) | 12 (2.6) | .045 | 6 (7.1) | 7 (4.2) | .368 |
| A, Minor stroke during hospitalization (No.) (%) | 3 (3.6) | 5 (1.1) | .111 | 3 (3.6) | 3 (1.8) | .404 |
| B, Major stroke during hospitalization (No.) (%) | 1 (1.2) | 6 (1.3) | 1.000 | 1 (1.2) | 4 (2.4) | .668 |
| Hyperperfusion syndrome during hospitalization (No.) (%) | 0 | 2 (0.4) | 1.000 | 0 | 0 | |
| Myocardial infarction during hospitalization (No.) (%) | 1 (1.2) | 0 | .154 | 1 (1.2) | 0 | .333 |
| Death during hospitalization (No.) (%) | 2 (2.4) | 2 (0.4) | .115 | 2 (2.4) | 0 | .110 |
| C, Minor stroke in 30-day hospitalization (No.) (%) | 0 | 4 (0.9) | 1.000 | 0 | 2 (1.2) | .554 |
| D, Major stroke in 30-day hospitalization (No.) (%) | 1 (1.2) | 2 (0.4) | .396 | 1 (1.2) | 1 (0.6) | 1.000 |
| E, Death in 30 days (including during hospitalization) (No.) (%) | 3 (3.6) | 3 (0.7) | .050 | 3 (3.6) | 1 (0.6) | .109 |
| Primary end point: A + B + C + D + E (No.) (%) | 7 (8.3) | 19 (4.1) | .101 | 7 (8.3) | 11 (6.6) | .611 |
| Re-intervention for restenosis during follow-up (No.) (%) | 9 (10.7) | 19 (4.1) | .026 | 9 (10.7) | 6 (3.6) | .044 |
| All-cause mortality during follow-up (No.) (%) | 33 (39.3) | 202 (43.9) | .473 | 33 (39.3) | 76 (45.2) | .419 |
| Cardiovascular death (No.) (%) | 25 (29.8) | 129 (28.0) | .792 | 25 (29.8) | 53 (31.6) | .885 |
| Noncardiovascular death (No.) (%) | 6 (7.1) | 64 (13.9) | .110 | 6 (7.1) | 19 (11.3) | .374 |
| Unknown death (No.) (%) | 2 (2.4) | 9 (2.0) | .682 | 2 (2.4) | 4 (2.4) | 1.000 |
| Mortality per 100 patient-years | 6.6 | 6.8 | 6.6 | 6.5 | ||
Note:—TIA indicates transient ischemic attack.